Cargando…
Antiviral Strategies
Viruses are obligatory intracellular parasites, whose replication depends on pathways and functions of the host cell. Consequently, it is difficult to define virus-specific functions as suitable targets for anti-infective therapy. However, significant progress has been made in the past 50 years towa...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120301/ https://www.ncbi.nlm.nih.gov/pubmed/19048195 http://dx.doi.org/10.1007/978-3-540-79086-0_1 |
_version_ | 1783514943105007616 |
---|---|
author | Müller, B. Kräusslich, Hans-Georg |
author_facet | Müller, B. Kräusslich, Hans-Georg |
author_sort | Müller, B. |
collection | PubMed |
description | Viruses are obligatory intracellular parasites, whose replication depends on pathways and functions of the host cell. Consequently, it is difficult to define virus-specific functions as suitable targets for anti-infective therapy. However, significant progress has been made in the past 50 years towards the development of effective and specific antivirals. In particular, human immunodeficiency virus, hepatitis C virus, and hepatitis B virus, which cause chronic infections affecting millions of individuals world-wide, are a major focus of antiviral research. Initially, antivirals were mainly directed against virus-specific enzymes; more recently, drugs inhibiting the steps of virus entry or release have been developed. Rational approaches towards drug development, based on information about structure and function of viral proteins and molecular mechanisms of virus-host interactions, have become increasingly successful. Novel strategies currently explored in basic research or preclinical studies include approaches targeting host factors important for virus replication, the exploitation of the innate immune response system as well as the use of gene silencing strategies aimed at interfering with viral gene expression. Today, a number of effective virostatics targeting various viral replication steps are approved for treatment of important viral diseases. However, the use of these drugs is limited by the rapid development of antiviral resistance, which represents a central problem of current antiviral therapy. |
format | Online Article Text |
id | pubmed-7120301 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71203012020-04-06 Antiviral Strategies Müller, B. Kräusslich, Hans-Georg Antiviral Strategies Article Viruses are obligatory intracellular parasites, whose replication depends on pathways and functions of the host cell. Consequently, it is difficult to define virus-specific functions as suitable targets for anti-infective therapy. However, significant progress has been made in the past 50 years towards the development of effective and specific antivirals. In particular, human immunodeficiency virus, hepatitis C virus, and hepatitis B virus, which cause chronic infections affecting millions of individuals world-wide, are a major focus of antiviral research. Initially, antivirals were mainly directed against virus-specific enzymes; more recently, drugs inhibiting the steps of virus entry or release have been developed. Rational approaches towards drug development, based on information about structure and function of viral proteins and molecular mechanisms of virus-host interactions, have become increasingly successful. Novel strategies currently explored in basic research or preclinical studies include approaches targeting host factors important for virus replication, the exploitation of the innate immune response system as well as the use of gene silencing strategies aimed at interfering with viral gene expression. Today, a number of effective virostatics targeting various viral replication steps are approved for treatment of important viral diseases. However, the use of these drugs is limited by the rapid development of antiviral resistance, which represents a central problem of current antiviral therapy. 2009 /pmc/articles/PMC7120301/ /pubmed/19048195 http://dx.doi.org/10.1007/978-3-540-79086-0_1 Text en © Springer-Verlag Berlin Heidelberg 2009 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Müller, B. Kräusslich, Hans-Georg Antiviral Strategies |
title | Antiviral Strategies |
title_full | Antiviral Strategies |
title_fullStr | Antiviral Strategies |
title_full_unstemmed | Antiviral Strategies |
title_short | Antiviral Strategies |
title_sort | antiviral strategies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120301/ https://www.ncbi.nlm.nih.gov/pubmed/19048195 http://dx.doi.org/10.1007/978-3-540-79086-0_1 |
work_keys_str_mv | AT mullerb antiviralstrategies AT krausslichhansgeorg antiviralstrategies |